This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grube, E. Articles by Gerckens, U. Search for Related Content PubMed PubMed Citation Articles by Grube, E. Articles by Gerckens, U. Related Collections Catheter-based coronary and valvular interventions: other Related Article

Original Articles

Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System

Eberhard Grube, MD; Lutz Buellesfeld, MD; Ralf Mueller, MD; Barthel Sauren, MD; Bernfried Zickmann, MD; Dinesh Nair, MD; Harald Beucher, MD; Thomas Felderhoff, MD; Stein Iversen, MD and Ulrich Gerckens, MD

From the Departments of Cardiology (E.G., L.B., U.G., R.M., D.N.), Cardiac Surgery (T.F., S.I.), and Anaesthesiology (B.S., B.Z.), HELIOS Heart Center Siegburg, Siegburg, Germany.

Correspondence to Eberhard Grube, MD, Department of Cardiology/Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany. E-mail grubee{at}aol.com

Received September 6, 2008; accepted October 31, 2008.

Background— Percutaneous aortic valve replacement is a new emerging technology for interventional treatment of severe aortic valve stenosis in surgical high-risk patients. This study was intended to provide a summary of the development and current safety and efficacy status of the self-expanding CoreValve Revalving prosthesis.

Method and Results— Between 2005 and 2008, we have enrolled 136 consecutive patients with percutaneous aortic valve replacement using the CoreValve prosthesis. In this prospective nonrandomized, single-center trial, we analyzed procedural outcome, complications and clinical status up to 1 year. First, second, and third generation of the CoreValve prosthesis were implanted in 10, 24, and 102 consecutive high-risk patients (logistic EuroScore: 23.1±15.0%) with severe symptomatic aortic valve stenosis. Mean transvalvular pressure gradient was 41.5±16.7 mm Hg. The procedural success rate increased from generation 1/2 to 3 from 70.0%/70.8% to 91.2% (P=0.003). The 30-day combined rate of death/stroke/myocardial infarction was 40.0%/20.8%/14.7% (P=0.11) for generation 1, 2, and 3, with no procedural death in generation 3. Pressure gradients improved significantly with a final mean gradient of 8.1±3.8 mm Hg. Overall functional status assessed by New York Heart Association class improved from 3.3±0.5 (pre) to 1.7±0.7 (post) (P<0.001) and remained stable in the follow-up.

Conclusion— In experienced hands, percutaneous aortic valve replacement with the CoreValve system for selected patients with severe aortic valve stenosis has a high acute success rate associated with a low periprocedural mortality/stroke rate as well as remarkable clinical and hemodynamic improvements, which persist over time. Additional studies are now required to confirm these findings, particularly head-to-head comparisons with surgical valve replacement in different risk populations.

Key Words: aortic valve disease • aortic stenosis • valve prosthesis • percutaneous approach

Related Article

Transcatheter Aortic Valve Implantation: Past, Present, and Future

Howard C. Herrmann
Circ Cardiovasc Interv 2008 1: 159-160. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				L. Buellesfeld, P. Wenaweser, U. Gerckens, R. Mueller, B. Sauren, G. Latsios, B. Zickmann, G. Hellige, S. Windecker, and E. Grube Transcatheter aortic valve implantation: predictors of procedural success--the Siegburg-Bern experience Eur. Heart J., December 27, 2009; (2009) ehp570v1. [Abstract] [Full Text] [PDF]

				G. Bruschi, F. De Marco, J. Oreglia, P. Colombo, P. Fratto, F. Lullo, R. Paino, M. Frigerio, L. Martinelli, and S. Klugmann Percutaneous Implantation of CoreValve Aortic Prostheses in Patients With a Mechanical Mitral Valve. Ann. Thorac. Surg., November 1, 2009; 88(5): e50 - e52. [Abstract] [Full Text] [PDF]

				S. Bleiziffer, H. Ruge, D. Mazzitelli, A. Hutter, A. Opitz, R. Bauernschmitt, and R. Lange Survival after transapical and transfemoral aortic valve implantation: Talking about two different patient populations J. Thorac. Cardiovasc. Surg., November 1, 2009; 138(5): 1073 - 1080. [Abstract] [Full Text] [PDF]

				L. F Tops, V. Delgado, F. van der Kley, and J. J Bax Percutaneous aortic valve therapy: clinical experience and the role of multi-modality imaging Heart, September 15, 2009; 95(18): 1538 - 1546. [Full Text] [PDF]

				D. H. Adams, A. C. Anyanwu, J. Chikwe, and F. Filsoufi The Year in Cardiovascular Surgery J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2389 - 2403. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				H. C. Herrmann Transcatheter Aortic Valve Implantation: Past, Present, and Future Circ Cardiovasc Interv, December 1, 2008; 1(3): 159 - 160. [Full Text] [PDF]